1 1 0 9 a r t i c l e s ABA biosynthesis is triggered in response to heat, cold, drought and other stressors 1,2 . Crop plants engineered to have increased ABA sensitivity show improved yield under conditions of moderate drought 3 , and the direct application of ABA or ABA analogs to plants in the field improves water-use efficiency 4 . Synthetic ABA agonists that activate plant stress-tolerance pathways therefore have potential to provide new options for managing stress tolerance and water use, which has important ramifications, as ~70% of fresh water is used for agriculture.
1 1 1 0 VOLUME 17 NUMBER 9 SEPTEMBER 2010 nature structural & molecular biology a r t i c l e s As observed previously for ABA-bound receptor structures, a complex network of polar and hydrophobic interactions facilitates pyrabactin's binding to PYR1. Pyrabactin's sulfonamide is positioned similarly to ABA's carboxylate and hydrogen-bonds to the amino group of Lys59. Both direct and water-mediated contacts coordinated by Glu94 and Glu141 explain the necessity of these residues for pyrabactin responsiveness in vivo as originally defined by mutational studies 5 (Fig. 1e) . These results show that ABA and pyrabactin exploit similar contacts with PYR1 to elicit the conformational changes in the gate and latch needed for receptor activation.
When bound to PYR1, the pyridyl and naphthyl rings of pyrabactin are packed against each other at an ~60° angle. To satisfy this conformation, the pyridyl nitrogen must pack close to the naphthyl ring ( Fig. 1f) , as its rotation would cause steric clash. In a previous analysis of pyrabactin structure-activity relationships, any substitution involving the pyridyl nitrogen led to a complete loss of activity in germination and hypocotyl growth assays, whereas changes to the naphthyl group had only a modest effect 5 . Notably, the PYR1-bound conformation of pyrabactin is energetically unfavorable for the inactive analog apyrabactin, in which the replacement of the pyridyl N with a C-H is predicted by semiempirical quantum-mechanical calculations to cause steric clash with the naphthyl group (Fig. 1f) . We suggest that this clash prevents apyrabactin from binding deeply enough in PYR1's pocket to allow gate closure. Thus, differences in the accessible conformations of these two ligands are sufficient to explain their differential effects on PYR1.
Pyrabactin binds PYL2 in a nonproductive mode
Our structure showed that pyrabactin, like ABA, triggers gate closure but suggested no obvious residues that might explain pyrabactin's selectivity. We reasoned that pyrabactin's selectivity could reflect a lack of binding to nonresponsive family members. To test this, we used PYL2 as a representative model because it does not show strong pyrabactin responsiveness in comparison to PYR1 (ref. 5) . In contrast to this expectation, NMR titration data show that pyrabactin binds PYL2 ( Fig. 2a) at comparable stoichiometry to that of PYR1. This, in turn, suggested that a nonproductive binding interaction could explain the differential effects of pyrabactin on PYR1 and PYL2. To investigate this, we solved the crystal structure of the PYL2-pyrabactin complex to 1.9-Å resolution ( Table 1) . As observed with PYR1, pyrabactin's pyridyl ring packs against the aromatic ring of Tyr124, but in PYL2, it slides ~2 Å away from the long C-terminal helix, allowing the naphthyl group to rotate ~90° into the space vacated by the pyridyl ring ( Fig. 2b) . Pyrabactin positions PYL2's latch in a similar conformation to that observed in PYR1 ( Fig. 2c) , though weak or missing electron density for latch residues 117 Gly-Glu-His 119 suggests that it may be partially disordered. Notably, the gate remains open, with the central proline (Pro92) shifted 9 Å away from its closed position relative to that in the PYL2-ABA and PYR1 P88S-pyrabactin complexes. Thus, pyrabactin binds within the ABA-binding pocket of both PYR1 and PYL2 but does not elicit gate closure in PYL2 due to nonproductive, incompletely buried ligand orientation ( Supplementary Fig. 3 ).
During refinement of our PYL2-pyrabactin model, analysis of the electron density in PYL2's ligand-binding pocket suggested that multiple pyrabactin conformations were present. To probe these binding orientations more directly, we exploited the anomalous X-ray scattering generated by pyrabactin's bromine atom to resolve multiple ligand conformations ( Table 1 ). The anomalous density map reveals two signals corresponding to the major orientation described above and a minor species representing a second unproductive ligand orientation in an ~2:1 ratio. Relative to the major PYL2 binding mode, the naphthyl ring revolves ~90° around the bromine-sulfur axis to pack against the aromatic ring of Tyr124, whereas the pyridyl ring rotates ~180° to pack against the naphthyl ring ( Fig. 2d) . This rearrangement moves the pyridyl nitrogen the greatest distance, ~5.5 Å, when the conformations are compared. Thus, the conclusion from these three X-ray datasets is that PYR1 enables a specific and productive pyrabactin binding orientation, whereas PYL2 accommodates multiple nonproductive orientations.
Ile110 and Ile62 position pyrabactin for agonist activity
Because the gate and latch loops are highly conserved and the PYR1 and PYL2 structures are very similar, we reasoned that subtle sequence differences between the pockets of PYR1 and PYL2 influence pyrabactin's binding orientations. To define the specific residues underlying this behavior, we screened for PYR1 mutants that respond to ABA but not pyrabactin using a mutagenized PYR1 library in a yeast-based receptor assay 5 . Sequence analysis of mutants that selectively block The pyridyl ring packs against the aromatic side chain of Tyr120 and the naphthyl group of pyrabactin. Contacts with the bromine atom and napthyl group of pyrabactin stabilize the gate in the closed conformation, as indicated by the location of the conserved proline in the Ser-Gly-Leu-Pro-Ala gate. (e) The sulfonamide linkage forms polar contacts in the base of the binding pocket and functions analogously to ABA's carboxylate group. (f) Based on AM1 calculations, packing interactions between the pyridyl ring and naphthyl group in the conformation adopted by pyrabactin when bound to PYR1 would result in steric clash (magenta) in apyrabactin. a r t i c l e s pyrabactin response identified a number of residues ( Supplementary  Table 1 ). Some have no obvious role in pyrabactin selectivity because they are conserved in responsive and nonresponsive family members or are located far from the ligand-binding pocket (for example, Lys170). We focused on the specific mutations I110V and I62V because they correspond to natural substitutions found in family members such as PYL2, PYL3 and PYL4 that are nonresponsive to pyrabactin. The side chains of both Ile110 and Ile62 project into the ligand-binding pockets of PYR/PYL proteins and make close contact with pyrabactin. These observations suggest that natural variation at positions homologous to Ile110 and Ile62 contribute to pyrabactin's selectivity. To test this, we constructed and analyzed PYR1 I62V, PYR1 I110V and PYR1 I110V I62V mutants; all mutants generated retain ABA responsiveness ( Fig. 3a) but achieved only partial PP2C interaction ( Fig. 3b) or inhibition ( Fig. 3c ) in response to saturating levels of pyrabactin. These results define Ile110 and Ile62 as key determinants of pyrabactin response and show that subtle changes in pocket residues control agonist activity.
Notably, the PP2C-inhibition curves for these PYR1 selectivity mutants achieve incomplete inhibition in response to saturating concentrations of pyrabactin ( Fig. 3c ), suggesting that a mixture of active and inactive receptor populations is formed. To interrogate the stability of these complexes in solution, we performed a comparative NMR analysis of a monomeric PYR1 mutant (PYR1 L166R) and the equivalent set of pyrabactin responsiveness mutants (PYR1 L166R I62V, PYR1 L166R I110V and PYR1 L166R I62V I110V) in the presence of saturating pyrabactin concentrations. NMR titration experiments indicate that PYR1 L166R binds ABA and pyrabactin with higher affinity than that of wild-type PYR1, suggesting that ligand binding may compete with PYR1 self-association. PYR1 L166R also retains ABA-dependent PP2C binding in a yeast two-hybrid assay, indicating that receptor function is not dependent on the dimer interface being intact.
An HSQC overlay of all four pyrabactinsaturated PYR1 L166R proteins shows a linear pattern of 1 H/ 15 N shift perturbations for multiple residues (Fig. 3d) , which is a hallmark of an equilibrium in which two conformations interconvert on microsecond-to-millisecond time scales 14 . The progression of HSQC signals for each PYR1-pyrabactin complex has the appearance of a titration experiment, as if the incorporation of each of the inactivating mutations increases the relative abundance of a new conformational state. Because the alternative binding mode observed in the PYL2-pyrabactin complex correlates with an 'open' gate-latch arrangement, we speculated that the loss of side chain methyl groups at positions 62 and 110 in the PYR1 binding pocket would permit pyrabactin to sample similar nonproductive orientations. In the case of Gly112, a latch residue that does not contact pyrabactin, a r t i c l e s the selectivity mutations progressively shift its HSQC signal toward the ligand-free 'open' chemical shift despite the presence of pyrabactin in the binding pocket. Strikingly, the magnitude of the chemical shift for each mutant relative to that of wild-type PYR1 is directly proportional to the residual PP2C activity observed at saturating pyrabactin concentrations ( Fig. 3e) . Because residues in the pocket, gate and latch respond coordinately, we conclude that the I62V and I110V mutations shift the ratio between the productive ligand orientation observed in PYR1 P88S-pyrabactin and a nonproductive orientation and that these states interconvert rapidly in solution.
Pyrabactin shifts orientation in reciprocal PYL2 mutants
Because removal of a δ methyl group at either Ile62 or Ile110 promotes nonproductive pyrabactin binding in PYR1, we reasoned that reciprocal mutations in PYL2 would have the opposite effect. Indeed, when compared to wild-type PYL2, the PYL2 V67I, PYL2 V114I and PYL2 V67I V114I mutants are increasingly pyrabactin sensitive (Fig. 4a) .
Likewise, maximal PP2C inhibition in response to pyrabactin levels rises substantially with the addition of each δ methyl group into the binding pocket ( Fig. 4b) , but ABA responses are not changed (Fig. 4c) .
To investigate the structural basis for this, we solved the PYL2 V114Ipyrabactin complex to 2.0-Å resolution ( Table 1) . Relative to the ligand orientation in the wild-type PYL2-pyrabactin structure (Fig. 4d) , pyrabactin binds PYL2 V114I in a single well-defined position resembling a productive ligand orientation in which the pyridyl ring is stacked between the aromatic ring of Tyr124 and the naphthyl ring ( Fig. 4e) a r t i c l e s observed in the PYR1 P88S-pyrabactin structure (Fig. 4f) . PYL2 V114I enables strong pyrabactin agonist activity, but like the reciprocal selectivity mutants in PYR1, it does not enable complete PP2C inhibition in response to pyrabactin, which implies the formation of a mixed population of open and closed gate conformations. We therefore suggest that the PYL2 V114I crystal structure captures a nonproductive state in which pyrabactin sits ~1.5 Å deeper in the PYL2 binding pocket than observed in the PYR1-pyrabactin structure. This subtle difference allows His119 to pack inside PYL2's pocket and block gate closure. Irrespective of the explanation for its open gate, this structure clearly reveals that the addition of a single δ methyl carbon in PYL2 V114I is sufficient to shift pyrabactin's binding orientation. The inverse trends in PP2C binding and inhibition for the PYR1 and PYL2 reciprocal mutants, the linear pattern of 1 H/ 15 N shift perturbations observed for the PYR1 mutants and the changes in pyrabactin orientation observed crystallographically in PYL2 and PYL2 V114I bolster our conclusion that removal of the δ methyl groups from Ile110 and Ile62 alters the pyrabactin orientation in PYR1.
DISCUSSION
Our structural comparisons and mutational analysis of pyrabactin binding to the ABA receptors PYR1 and PYL2 has shown that subtle changes in the binding pockets of PYR/PYL proteins control ligand orientation inside the pocket, and this is sufficient to explain whether pyrabactin acts as an effective receptor agonist. One question this raises is whether the natural variation in pocket-lining residues has functional relevance in vivo. One possibility is that plants may contain endogenous signals that exploit this variability to achieve selective receptor activation, a hypothesis we are currently investigating. We initiated our studies anticipating that pocket variation would control pyrabactin binding; however, this is not the case. Our results are consistent with the frequently observed promiscuity of ligand binding to START proteins and show that a key feature of agonist activity is not receptor binding per se but stabilization of gate closure. The implications of our work for agonist design are important, and we now have several tools with which to measure and monitor effective gate closure. Additionally, we suggest that the chemical modification of pyrabactin at sites designed to alter ligand orientation will enable agonist design for other PYR/PYL receptors.
Note added in proof: Results presented here are consistent with structural analyses of pyrabactin recognition 15, 16 .
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Crystal structures of PYR1 P88Spyrabactin, PYL2-pyrabactin and PYL2 V114I-pyrabactin were deposited under accession numbers 3NJO, 3NJ0 and 3NJ1, respectively.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
